Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Sept. 16 — In a Sept. 16 letter, physician groups, addiction agencies and consumer advocacy organizations urged the Senate Finance Committee to make public the results of a 2012 investigation into financial ties between producers of pain drugs and the organizations that aggressively promote the drugs.
In May 2012, Sens. Max Baucus (D-Mont.) and Charles E. Grassley (R-Iowa) sent letters to Purdue Pharma, Endo Pharmaceuticals and Johnson & Johnson asking about their connections with medical groups and physicians who have advocated the increased use of opioids. Baucus and Grassley also asked seven medical groups to produce information about their financial ties and collaborations with opioid manufacturers.
The senators said they were trying to establish whether the groups have promoted misleading information about risks and benefits of opioids while receiving financial support from opioid manufacturers.
“To bring our nation’s epidemic of opioid addiction to an end, we must reduce overprescribing of opioids,” the letter said. “This goal will be difficult to achieve if opioid makers, and the groups they fund, continue to promote aggressive and inappropriate prescribing. We urge you to release the findings from the Committee’s investigation of their activities.”
The aggressive push to prescribe opioid painkillers for common conditions like low back pain, where risks of use outweigh benefits, has led to soaring rates of addiction, overdose deaths, infants born opioid-dependent and other health and social problems, the groups said.
“Opioid overdoses, once rare in the United States, have caused more than 220,000 deaths (175,000 from painkillers and 45,000 from heroin) since 1999,” the letter said. “That is more than double the number of American lives lost in Vietnam, Iraq and Afghanistan combined. In other words, the efforts by opioid manufacturers to increase opioid prescribing have led to a public health catastrophe that may take decades for our country to recover from.”
The letter was signed by 36 groups, including Public Citizen, the Physicians for Responsible Opioid Prescribing (PROP), American Addiction Centers, Horizon Health Services, the National Coalition Against Prescription Drug Abuse and the Hazelden Betty Ford Foundation.
The Senate Finance Committee is chaired by Sen. Orrin G. Hatch (R-Utah). Julia Lawless, a spokeswoman for the Senate Finance Committee, told Bloomberg BNA in an e-mail that “while this was an investigation closed under a previous Chairman during another Congress, Chairman Hatch believes this is an issue of serious concern and will be talking with members of the Finance Committee on how they would like to move forward.”
A spokesman for Purdue Pharma told Bloomberg BNA in an e-mail that the company agrees that “prescription drug abuse is a serious problem, which is why we collaborate with policymakers, law enforcement and public health experts to address the issue of opioid overuse and abuse.”
“We responded to the committee's questions at the time they were received,” the spokesman said.
To contact the reporter on this story: Bronwyn Mixter in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Nancy Simmons at email@example.com
The letter is at http://www.citizen.org/documents/2275.pdf.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)